Literature DB >> 33309946

On selecting the critical boundary functions in group-sequential trials with two time-to-event outcomes.

Toshimitsu Hamasaki1, H M James Hung2, Chin-Fu Hsiao3, Scott R Evans4.   

Abstract

We investigate selection of critical boundary functions for testing the hypotheses of two time-to-event outcomes as both primary endpoints or a primary and a secondary endpoint in group-sequential clinical trials, where (1) the effect sizes of endpoints are unequal, or (2) one endpoint is for short-term evaluation and the other for long-term evaluation. Bonferroni-Holm and fixed-sequence procedures are considered. We assess the effects of the magnitudes of the hazard ratios and the correlation between the endpoints on statistical powers and provide guidance for consideration.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Bonferroni-Holm procedure; Conjunctive power; Disjunctive power; Fixed-sequence procedure; Logrank test; O'Brien-Fleming-type boundary function; Pocock-type boundary function

Year:  2020        PMID: 33309946      PMCID: PMC7954908          DOI: 10.1016/j.cct.2020.106244

Source DB:  PubMed          Journal:  Contemp Clin Trials        ISSN: 1551-7144            Impact factor:   2.226


  12 in total

1.  Computations for group sequential boundaries using the Lan-DeMets spending function method.

Authors:  D M Reboussin; D L DeMets; K M Kim; K K Lan
Journal:  Control Clin Trials       Date:  2000-06

Review 2.  Statistical challenges in a regulatory review of cardiovascular and CNS clinical trials.

Authors:  H M James Hung; Sue-Jane Wang; Peiling Yang; Kun Jin; John Lawrence; George Kordzakhia; Tristan Massie
Journal:  J Biopharm Stat       Date:  2016       Impact factor: 1.051

3.  Statistical considerations for testing multiple endpoints in group sequential or adaptive clinical trials.

Authors:  H M James Hung; Sue-Jane Wang; Robert O'Neill
Journal:  J Biopharm Stat       Date:  2007       Impact factor: 1.051

4.  Hierarchical testing of multiple endpoints in group-sequential trials.

Authors:  Ekkehard Glimm; Willi Maurer; Frank Bretz
Journal:  Stat Med       Date:  2010-01-30       Impact factor: 2.373

5.  Allocating recycled significance levels in group sequential procedures for multiple endpoints.

Authors:  Dong Xi; Ajit C Tamhane
Journal:  Biom J       Date:  2014-10-30       Impact factor: 2.207

6.  Group-Sequential Strategies in Clinical Trials with Multiple Co-Primary Outcomes.

Authors:  Toshimitsu Hamasaki; Koko Asakura; Scott R Evans; Tomoyuki Sugimoto; Takashi Sozu
Journal:  Stat Biopharm Res       Date:  2015       Impact factor: 1.452

7.  A group sequential Holm procedure with multiple primary endpoints.

Authors:  Yining Ye; Ai Li; Lingyun Liu; Bin Yao
Journal:  Stat Med       Date:  2012-12-14       Impact factor: 2.373

8.  Sample size determination in group-sequential clinical trials with two co-primary endpoints.

Authors:  Koko Asakura; Toshimitsu Hamasaki; Tomoyuki Sugimoto; Kenichi Hayashi; Scott R Evans; Takashi Sozu
Journal:  Stat Med       Date:  2014-03-27       Impact factor: 2.373

9.  Group-sequential logrank methods for trial designs using bivariate non-competing event-time outcomes.

Authors:  Tomoyuki Sugimoto; Toshimitsu Hamasaki; Scott R Evans; Susan Halabi
Journal:  Lifetime Data Anal       Date:  2019-04-12       Impact factor: 1.588

10.  Surrogate endpoints for overall survival in chemotherapy and radiotherapy trials in operable and locally advanced lung cancer: a re-analysis of meta-analyses of individual patients' data.

Authors:  Audrey Mauguen; Jean-Pierre Pignon; Sarah Burdett; Caroline Domerg; David Fisher; Rebecca Paulus; Samithra J Mandrekar; Chandra P Belani; Frances A Shepherd; Tim Eisen; Herbert Pang; Laurence Collette; William T Sause; Suzanne E Dahlberg; Jeffrey Crawford; Mary O'Brien; Steven E Schild; Mahesh Parmar; Jayne F Tierney; Cécile Le Pechoux; Stefan Michiels
Journal:  Lancet Oncol       Date:  2013-05-14       Impact factor: 41.316

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.